

Aaron R Mangold

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/896395/publications.pdf>

Version: 2024-02-01

67
papers

781
citations

567281

15
h-index

580821

25
g-index

68
all docs

68
docs citations

68
times ranked

1010
citing authors

#	ARTICLE	IF	CITATIONS
1	Skin Cancer Knowledge, Attitudes and Sun Protection Practices in the Hispanic Population: A Cross-Sectional Survey. <i>Journal of Racial and Ethnic Health Disparities</i> , 2023, 10, 1293-1303.	3.2	4
2	Deep learning for dermatologists: Part II. Current applications. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1352-1360.	1.2	27
3	Comorbidities and diabetic complications in patients with necrobiosis lipidica. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 891-894.	1.2	2
4	Primary cutaneous CD4+ small/medium T-cell lymphoproliferative disorder: Diagnosis and management. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1167-1169.	1.2	7
5	Clinical and morphological features of necrobiosis lipidica. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1133-1135.	1.2	9
6	Decreasing physician Medicare reimbursement for dermatology services. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1154-1156.	1.2	8
7	Necrobiosis lipidica-associated cutaneous malignancy. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1428-1429.	1.2	3
8	Deep learning for dermatologists: Part I. Fundamental concepts. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1343-1351.	1.2	20
9	Ruxolitinib Cream in the Treatment of Cutaneous Lichen Planus: A Prospective, Open-Label Study. <i>Journal of Investigative Dermatology</i> , 2022, 142, 2109-2116.e4.	0.7	20
10	Medicare Part D prescription trends in the use and cost of dermatology medications. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 916-918.	1.2	2
11	Histopathologic features of necrobiosis lipidica. <i>Journal of Cutaneous Pathology</i> , 2022, 49, 692-700.	1.3	6
12	Secukinumab for the treatment of adult-onset pityriasis rubra pilaris: a single-arm clinical trial with transcriptomic analysis. <i>British Journal of Dermatology</i> , 2022, 187, 650-658.	1.5	19
13	Dermoscopic characteristics of microcystic adnexal carcinoma, desmoplastic trichoepithelioma, and morpheaform basal cell carcinoma. <i>International Journal of Dermatology</i> , 2021, 60, e83-e84.	1.0	4
14	The prognostic value of inositol polyphosphate 5â€phosphatase in cutaneous squamous cell carcinoma in the general population. <i>International Journal of Dermatology</i> , 2021, 60, e427-e429.	1.0	0
15	Evaluation of the Safety of Calcitonin Gene-Related Peptide Antagonists for Migraine Treatment Among Adults With Raynaud Phenomenon. <i>JAMA Network Open</i> , 2021, 4, e217934.	5.9	24
16	Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination. <i>Leukemia and Lymphoma</i> , 2021, 62, 2554-2555.	1.3	24
17	A rare case of childhood mucous membrane pemphigoid involving the oral and genital mucosa. <i>Pediatric Dermatology</i> , 2021, 38, 904-907.	0.9	1
18	Survival and glycemic control in patients with co-existing squamous cell carcinoma and diabetes mellitus. <i>Future Science OA</i> , 2021, 7, FSO683.	1.9	4

#	ARTICLE	IF	CITATIONS
19	Rates of Upstaging, Between Diagnosis and Surgery, and Clinical Management of Metastatic Cutaneous Squamous Cell Carcinoma. <i>Dermatologic Surgery</i> , 2021, Publish Ahead of Print, 12-16.	0.8	0
20	Primary cutaneous epidermotropic marginal zone B-cell lymphoma treated with total skin electron beam therapy. <i>JAAD Case Reports</i> , 2021, 15, 15-18.	0.8	3
21	How to Sequence Therapies in Mycosis Fungoides. <i>Current Treatment Options in Oncology</i> , 2021, 22, 101.	3.0	3
22	Bexarotene. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2519-2522.	3.0	1
23	Blue light photodynamic therapy with 5-aminolevulinic acid in refractory mycosis fungoides: A prospective, open-label study. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 969-971.	1.2	4
24	Cutaneous B cell pseudolymphoma treated with rituximab and methotrexate. <i>Dermatology Online Journal</i> , 2021, 27, .	0.5	4
25	Consolidation of US dermatology practices. <i>International Journal of Dermatology</i> , 2021, , .	1.0	0
26	Prognostic value of inositol polyphosphate-5-phosphatase expression in recurrent and metastatic cutaneous squamous cell carcinoma. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 846-853.	1.2	14
27	Regression of mycosis fungoides with largeâ€œcell transformation following skin biopsy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e82-e84.	2.4	1
28	Improving Access to Care Through the Establishment of a Local, Teledermatology Network. <i>Telemedicine Journal and E-Health</i> , 2020, 26, 935-940.	2.8	14
29	Immunosuppression-associated primary cutaneous plasmablastic lymphoma secondary to romidepsin. <i>JAAD Case Reports</i> , 2020, 6, 19-22.	0.8	3
30	Clinical outcomes of solid organ transplant recipients with metastatic cancers who are treated with immune checkpoint inhibitors: A singleâ€œcenter analysis. <i>Cancer</i> , 2020, 126, 4780-4787.	4.1	19
31	A case of pediatric lymphomatoid papulosis treated with photodynamic therapy and narrowband ultraviolet B. <i>Pediatric Dermatology</i> , 2020, 37, 881-883.	0.9	4
32	Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations. <i>PLoS ONE</i> , 2020, 15, e0230306.	2.5	27
33	Use of Skin Cancer Procedures, Medicare Reimbursement, and Overall Expenditures, 2012-2017. <i>JAMA Network Open</i> , 2020, 3, e2025139.	5.9	6
34	The policy dimensions, regulatory landscape, and market characteristics of teledermatology in the United States. <i>JAAD International</i> , 2020, 1, 202-207.	2.2	6
35	Title is missing!. , 2020, 15, e0230306.		0
36	Title is missing!. , 2020, 15, e0230306.		0

#	ARTICLE	IF	CITATIONS
37	Title is missing!. , 2020, 15, e0230306.		0
38	Title is missing!. , 2020, 15, e0230306.		0
39	Survival and glycemic control in patients with coexisting melanoma and diabetes mellitus. Future Science OA, 2019, 5, FSO368.	1.9	7
40	Management of Hailey-Hailey disease with Castellani paint. JAAD Case Reports, 2019, 5, 855-856.	0.8	3
41	The prognostic value of inositol polyphosphate 5-phosphatase in cutaneous squamous cell carcinoma. Journal of the American Academy of Dermatology, 2019, 80, 626-632.e1.	1.2	16
42	Radiation Recall Dermatitis After the Use of Pralatrexate for Peripheral T-cell Lymphoma. Advances in Radiation Oncology, 2019, 4, 31-34.	1.2	2
43	Syngotropic and folliculotropic mycosis fungoides with mycosis fungoides-associated vasculopathic ulcers. JAAD Case Reports, 2019, 5, 231-233.	0.8	4
44	Impact of standardized templates and skin cancer learning modules for teledermatology consultations. International Journal of Dermatology, 2019, 58, 1423-1429.	1.0	9
45	Density and distribution of acral melanocytic nevi and acral melanomas on the plantar surface of the foot. Journal of the American Academy of Dermatology, 2019, 80, 790-792.e2.	1.2	5
46	Chemoprevention agents for melanoma: A path forward into phase 3 clinical trials. Cancer, 2019, 125, 18-44.	4.1	29
47	Dermoscopic Description of Fibroepithelioma of Pinkus with Negative Network. Dermatology Practical and Conceptual, 2019, 9, 246-247.	0.9	2
48	Melanoma mimicking Rosai-Dorfman disease. Journal of Cutaneous Pathology, 2018, 45, 355-359.	1.3	5
49	The Use of Central Pathology Review With Digital Slide Scanning in Advanced-stage Mycosis Fungoides and S�azary Syndrome. American Journal of Surgical Pathology, 2018, 42, 726-734.	3.7	17
50	Frequent loss of inositol polyphosphate 5-phosphatase in oropharyngeal squamous cell carcinoma. Journal of the European Academy of Dermatology and Venereology, 2018, 32, e36-e37.	2.4	7
51	Clinical and histopathologic features of paraneoplastic granuloma annulare in association with solid organ malignancies: A case-control study. Journal of the American Academy of Dermatology, 2018, 79, 913-920.e1.	1.2	17
52	Systemic scleroderma and lupus panniculitis with atypical clinical features: A case report and comprehensive review. JAAD Case Reports, 2018, 4, 789-793.	0.8	3
53	Unicentric castleman disease complicated by paraneoplastic bronchiolitis obliterans and pemphigus. Respiratory Medicine Case Reports, 2018, 25, 129-132.	0.4	8
54	Educational and practice gaps in the management of volar melanocytic lesions. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1450-1455.	2.4	9

#	ARTICLE	IF	CITATIONS
55	Dermoscopic features of cutaneous Langerhans cell histiocytosis. <i>European Journal of Dermatology</i> , 2018, 28, 88-89.	0.6	0
56	Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy. <i>Melanoma Management</i> , 2017, 4, 13-37.	0.5	97
57	Acral Melanoma and Mechanical Stress on the Plantar Surface of the Foot. <i>New England Journal of Medicine</i> , 2017, 377, 395-396.	27.0	50
58	Dermoscopic Findings of Irritant "Poral" Reactions to Cobalt During Patch Testing. <i>Dermatitis</i> , 2017, 28, 367-367.	1.6	4
59	Early clinical manifestations of SÃ©zary syndrome: A multicenter retrospective cohort study. <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 719-727.	1.2	34
60	Risk Factors Predicting Positive Margins at Primary Wide Local Excision of Cutaneous Melanoma. <i>Dermatologic Surgery</i> , 2016, 42, 646-652.	0.8	32
61	Chronic interstitial granulomatous dermatitis in coccidioidomycosis. <i>British Journal of Dermatology</i> , 2016, 174, 881-884.	1.5	6
62	Concomitant pemphigus herpetiformis and sarcoidosis. <i>JAAD Case Reports</i> , 2016, 2, 436-438.	0.8	1
63	Diseases of the tongue. <i>Clinics in Dermatology</i> , 2016, 34, 458-469.	1.6	85
64	Good syndrome and lichen planus: case and review. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 1828-1830.	2.4	8
65	Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, e205-e206.	1.2	13
66	Treatment of epidermolysis bullosa pruriginosa using systemic and topical agents. <i>Journal of the American Academy of Dermatology</i> , 2014, 70, e136-e137.	1.2	6
67	Flashback phenomenon and residual neurological deficits after the use of "bath salt" 3, 4-methylenedioxypropylvalerone. <i>World Journal of Emergency Medicine</i> , 2014, 5, 63.	1.0	4